RCE recce pharmaceuticals ltd

Ann: RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program, page-196

  1. 4,506 Posts.
    lightbulb Created with Sketch. 1602
    For the US patent application, they received a “Final Rejection” notice from the examiners on 8th July 2020.
    Amendments were submitted by Recce on 7th October 2020, so the jury’s out and we’re at the examiners’ mercy.

    You can download all correspondence here:

    US20180338994 - ANTI-VIRUS AGENT AND METHOD FOR TREATMENT OF VIRAL INFECTIONUS20180338994 - ANTI-VIRUS AGENT AND METHOD FOR TREATMENT OF VIRAL INFECTION
    https://patentscope.wipo.int/search/en/detail.jsf?docId=US234195945

    It doesn’t look like they’ve requested examination for the Australian application yet.
    They have until 5 years from the filing date to do so.

    AU2017220391 - ANTI-VIRUS AGENT AND METHOD FOR TREATMENT OF VIRAL INFECTION
    https://patentscope.wipo.int/search/en/detail.jsf?docId=AU215296824
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
30.0¢
Change
-0.010(3.23%)
Mkt cap ! $86.51M
Open High Low Value Volume
30.5¢ 32.0¢ 29.5¢ $30.88K 101.2K

Buyers (Bids)

No. Vol. Price($)
2 21103 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
32.0¢ 15000 1
View Market Depth
Last trade - 15.59pm 26/06/2025 (20 minute delay) ?
RCE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.